


## Product Information

### BAY u9773

Product Number **B9680**Storage Temperature  $-70\text{ }^{\circ}\text{C}$ 

Cas #: 134733-55-4

Synonyms: 6(R)-(4'-Carboxyphenylthio)-5(S)-hydroxy-7(E),11(Z)14(Z)-eicosatetrenoic acid



### Product Description

Molecular Formula:  $\text{C}_{27}\text{H}_{36}\text{S}\text{O}_5$ 

Molecular weight: 472.6 (anhydrous)

Supplied as white solid

Purity: &gt;99% by HPLC

The leukotrienes (LTs) are eicosanoids that are synthesized from arachidonic acid via the 5-lipoxygenase pathway.<sup>1</sup> All LTs are proinflammatory. The chemoattractant leukotriene,  $\text{LTB}_4$ , has potent chemotactic effects on leukocytes. The cysteinyl-leukotrienes ( $\text{CysLT}_2$ ;  $\text{LTC}_4$ ,  $\text{LTD}_4$  and  $\text{LTE}_4$ ) stimulate mucus secretion and the contraction of airway and vascular smooth muscle. The  $\text{CysLT}_2$ s are potent mediators of inflammatory diseases including asthma, inflammatory bowel syndrome, and psoriasis.<sup>1</sup> In asthma, they participate in both the bronchoconstriction and the chronic inflammatory components (mucus hypersecretion, plasma extravasation, mucosal edema, and eosinophil recruitment) of the disease.<sup>2</sup>

The  $\text{CysLT}$  functions are mediated via specific plasma membrane receptors belonging to the superfamily of G protein-coupled receptors. Currently there is evidence for the existence of two  $\text{CysLT}$  receptor subtypes,  $\text{CysLT}_1$  and  $\text{CysLT}_2$ . The  $\text{CysLT}_1$  receptor has been studied more extensively because of the availability of specific antagonists. The  $\text{CysLT}_2$  receptor was defined

pharmacologically as the receptor that is not inhibited by  $\text{CysLT}_1$ -specific antagonists.<sup>3,4</sup>

The leukotriene analog BAY u9773 was originally designated as a dual  $\text{CysLT}_1/\text{CysLT}_2$  antagonist. However, in kinetic studies with a newly cloned  $\text{CysLT}_2$  receptor, BAY u9773 was found to be an antagonist at  $\text{CysLT}_1$  sites and a partial agonist at the  $\text{CysLT}_2$  receptor. Thus, BAY u9773 may be classified as a subtype selective agonist for the  $\text{CysLT}_2$  receptor and a new selective tool for the studies of the physiological role of the  $\text{CysLT}_2$  receptor in cardiac, neuronal, endocrine and inflammatory circuits.<sup>5</sup>

### Preparation Instructions

Soluble in DMSO and ethanol at &gt;25 mg/ml.

### Storage/Stability

Store at  $-70\text{ }^{\circ}\text{C}$  for up to one year.

### References

1. Samuelsson, B., et al., Leukotrienes and lipoxins: structures, biosynthesis and biological effects. *Science* **237**, 1171-1176 (1987).
2. Nicosia, S., et al., Leukotrienes as mediators of asthma. *Pulm. Pharmacol. Ther.* **14**, 3-19 (2001).
3. Ravasi, E., et al., A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene  $\text{C}_4$  binding site not coupled to contraction in human lung parenchyma. *Mol. Pharmacol.* **57**, 1182-1189 (2000).
4. Back, M., et al., Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. *Eur. J. Pharmacol.* **401**, 381-388 (2000).
5. Nothacker, H-P., et al., Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. *Mol. Pharmacol.* **58**, 1601-1608 (2000).

AH 05/02

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.